About
Contact & Profiles
A5092786711
Research Areas
- Receptor Mechanisms and Signaling
- Synthesis of β-Lactam Compounds
- Ion channel regulation and function
- Cardiac electrophysiology and arrhythmias
- Antiplatelet Therapy and Cardiovascular Diseases
- Platelet Disorders and Treatments
University of Bristol
2023
Lung Institute
2023
Imperial College London
2023
Abstract Background and Purpose Ticagrelor is labelled as a reversible, direct‐acting platelet P2Y 12 receptor (P2Y R) antagonist that indicated clinically for the prevention of thrombotic events in patients with acute coronary syndrome (ACS). As many antiplatelet drugs, ticagrelor therapy increases bleeding risk patients, which may require transfusion emergency situations. The aim this study was to further examine reversibility at R. Experimental Approach Studies were performed human...
10.1111/bph.16204
article
EN
cc-by
British Journal of Pharmacology
2023-08-02
β
10.1161/circresaha.123.323174
article
EL
cc-by
Circulation Research
2023-10-23
Coming Soon ...